Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malaria - antiprotozoals - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children.consideration should be given to official guidance on the appropriate use of antimalarial agents.

Tanzanya - İngilizce - Tanzania Medicinces & Medical Devices Authority

salama pharmaceuticals limited, tanzania - ramipril - capsules, hard - 2.5 mg

Bangladeş - İngilizce - DGDA (Directorate General of Drug Administration)

amico laboratories ltd. - rosuvastatin - tablet - 5 mg

Bangladeş - İngilizce - DGDA (Directorate General of Drug Administration)

amico laboratories ltd. - rosuvastatin - tablet - 10 mg

ABD - İngilizce - NLM (National Library of Medicine)

amivas, inc - artesunate (unii: 60w3249t9m) (.alpha.-dihydroartemisinin - unii:x0uiv26abx) - artesunate for injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. treatment of severe malaria with artesunate for injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen [see dosage and administration (2.1)] . limitations of use artesunate for injection does not treat the hypnozoite liver stage forms of plasmodium and will therefore not prevent relapses of malaria due to plasmodium vivax or plasmodium ovale . concomitant therapy with an antimalarial agent such as an 8-aminoquinoline drug is necessary for the treatment of severe malaria due to p. vivax or p. ovale [see dosage and administration (2.1)] . known serious hypersensitivity to artesunate, such as anaphylaxis [see warnings and precautions (5.2) and adverse reactions (6.2)] . there are serious risks to the mother and fetus associated with untreated severe malaria during pregnancy; delaying treatment of severe malaria in pregnancy may result in ser

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - amivantamab, quantity: 350 mg - injection, concentrated - excipient ingredients: methionine; disodium edetate; histidine; polysorbate 80; histidine hydrochloride monohydrate; water for injections; sucrose - rybrevant has provisional approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that has an activating epidermal-growth factor receptor (egfr) exon 20 insertion mutation, whose disease has progressed on or after platinum-based chemotherapy.,the decision to approve this indication has been made on the basis of objective response rate and duration of response in a single arm study. continued approval of this indication depends on verification and description of benefit in a confirmatory study.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - bupivacaine hydrochloride - solution for injection - 2.5 milligram(s)/millilitre - amides; bupivacaine

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - bupivacaine hydrochloride - solution for injection - 0.25 percent weight/volume - amides; bupivacaine

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - bupivacaine hydrochloride - solution for injection - 0.5 percent weight/volume - amides; bupivacaine

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals (ireland) ltd - bupivacaine hydrochloride - solution for injection - 0.25 %w/v - amides